Israeli-developed oral COVID-19 vaccine strikes deal with Mexican lab

Source: MercoPress

Pharmaceutical companies from Israel and Mexico have announced an oral vaccine against COVID-19 is to be marketed across Latin America shortly.

The Mexican company Genomma Lab and the Israeli pharmaceutical company Oramed have announced the formation of a strategic alliance (50/50) to develop the tests to market the drug regionally.

The Oravax vaccine is composed of three specific proteins that resemble components of the virus, including some proteins that are less susceptible to mutation, so it can potentially be more effective in protecting against current and future variants of the coronavirus was reported.




Discusiones sobre el mismo tema

URL de retroenlace :

Fuente de los comentarios de esta entrada